Method of reducing side effects of targeted radiation therapy and of gadolinium in magnetic resonance imaging with DTPA esters
Oral DTPA esters like C2E2 effectively bind and excrete free toxic cations from radioligand therapies and gadolinium-based MRI agents, addressing systemic toxicity and enhancing therapeutic efficacy by reducing side effects in healthy tissues.
Patent Information
- Application Number
- PCT/US2026/027020
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Radioligand therapies using isotopes such as Lu-177 and Ac-225 cause significant non-target toxicity and side effects due to the systemic redistribution of radionuclides and gadolinium-based contrast agents in MRI leading to toxicity in healthy tissues, while existing oral DTPA prodrugs face manufacturing challenges and toxicity concerns.
Orally administered DTPA esters, such as C2E2, with ester groups masking carboxylic acid groups to enhance membrane permeability, bind free toxic cations and their decay products, preventing tissue deposition and enhancing excretion through the kidneys.
Reduces non-target toxicity by scavenging free radionuclides and gadolinium, minimizing side effects in tissues like kidneys, bone marrow, and salivary glands, and allowing higher therapeutic doses with reduced adverse events.
Smart Images

Figure US2026027020_12112026_PF_FP_ABST
Abstract
Description
[0001] Method of Reducing Side Effects of Targeted Radiation Therapy and of Gadolinium in Magnetic Resonance Imaging with DTPA Esters
[0002] Background
[0003] Radioligand therapies using isotopes such as Lu- 177 and Ac-225 have demonstrated efficacy in targeting cancer cells via tumor-associated membrane antigens (TAMAs), including but not limited to PSMA, HER2, EGFR, and CD20. However, a significant portion of administered radionuclides or their decay byproducts after time circulate systemically, redistributing to healthy tissues and causing toxicity, particularly to radiosensitive organs.
[0004] Radiolabeled therapeutic agents used in this method are conjugated to chelating ligands or "cages" — such as DOTA or Macropa derivatives — that stably coordinate the radionuclide during circulation. These ligands are essential to prevent toxicity from free radionuclide ions and to enable tumor- specific delivery. However, radioactive decay, particularly in alpha emitters like Actinium-225, can liberate highly toxic daughter nuclides due to nuclear recoil energy, often detaching them from the ligand complex. This necessitates secondary chelation via orally administered DTPA prodrugs to capture and eliminate the circulating decay products.
[0005] One cage chelator is 2,2',2'',2'''-(l,4,7,10-tetraazacyclododecane-l,4,7,10-tetrayl jtetraacetic acid (DOTA).
[0006]
[0007] DOTA PLUVICTO (Lutetium (177Lu) vipivotide tetraxetan or Lu-PSMA-617) is an FDA-approved targeted radioisotope that binds to the prostate specific membrane antigen (PSMA).Tt is approved for the treatment of pro state- specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
[0008]
[0009] Lu-PSMA-617
[0010] Another cage or polyvalent ligand proposed for chelating radioisotopes in targeted radiotherapy is the diaza-18-crown-6 macrocyclic chelator JHpmacropa and derivatives thereof, such as H2BZmacropa.
[0011]
[0012] Targeted radioligand agents using the macropa chelators, such as Trillium™ are being developed by Ratio Therapeutics.
[0013] Systemically administered targeted targeted cationic metal complexes are effective to treat various cancers. But they also cause significant non-target toxicity and side effects, including myelosuppression, bone deposition of the radioisotope, and salivary gland damage, which may be permanent. New solutions to reduce the non-target toxicity and side effects of targeted radioisotope therapy are needed.
[0014] Magnetic resonance imaging (MRI) is a widely used medical imaging technique. Gadolinium-based contrast agents (GBCA) are used in medical imaging to enhance anatomical structures and assess perfusion. The gadolinium cation (Gd3+) is paramagnetic and shortens the T1 (longitudinal) relaxation time of protons, thereby producing high T1 signal intensity on magnetic resonance imaging (MRI). Gadolinium is a heavy metal from the lanthanide group with an atomic number of 64. It is toxic to living things. Gadolinium contrast agents have been linked to kidney damage, pancreatitis, and neurological symptoms including brain fog. New solutions to reduce these side effects of use of gadolinium in MRI are needed.
[0015] Prior art approaches to oral administration of DTPA-class chelators (for example, U. S. Patent No. 7,914,767 to SRI International) have relied on co-formulation with permeation enhancers to achieve sufficient gastrointestinal absorption of Ca-DTPA or Zn-DTPA. Such permeation enhancers carry their own toxicity concerns, are difficult to manufacture in stable oral dosage forms, and have not produced an FDA-approved oral DTPA product to date. The compounds of Formula I described herein achieve oral bioavailability through a fundamentally different mechanism: ester prodrug chemistry. The ester groups (for example, ethyl esters in C2E2) mask two of the carboxylic-acid groups of DTPA, increasing membrane permeability approximately ten-fold over DTPA itself (as measured by Caco-2 permeability assays) without requiring any permeation enhancer. Following intestinal absorption, the parent C2E2 retains chelation activity in plasma, while sequential ester hydrolysis in vivo regenerates partially esterified C2E1 and ultimately DTPA, each of which retains useful metal-binding activity.Furthermore, no prior art teaches the use of an orally bioavailable DTPA ester prodrug as an adjunct to targeted radioligand therapy for the specific purpose of scavenging free radionuclides and radioactive decay daughter isotopes released in vivo from a separately administered tumor-targeted radionuclide-chelator complex. The methods disclosed herein are directed to that distinct, previously unaddressed clinical need.
[0016] Summary
[0017] Methods are disclosed for using a family of binding agents or chelators, including diethylenetriaminepentaacetic acid (DTPA) di-ethyl ester, with the formal name 6,9-bis(carboxymethyl)-3-(2-ethoxy-2-oxoethyl)-l 1-oxo- 12-oxa-3,6.9-triazatetradecan- 1-oic acid, known as C2E2, and other esters and derivatives of diethylenetriaminepentaacetic acid (DTPA) that are stable to digestion and thus can be administered orally with systemic absorption from the oral route into blood to reduce non-target toxicity and side effects of systemic administration of toxic cation complexes, including targeted radionuclides and gadolinium contrast agents. After administration, the binding agents bind the free toxic cations and their toxic decay product isotopes (in the case of radioactive cations) arising from administration of toxic cation-chelator complexes including therapeutic targeted radionuclidechelator complexes. The original radionuclide and its radioactive decay products (both radioactive and non-radioactive) leach from the cage in which it was administered. The release happens by simple kinetic equilibrium of the bound and unbound species in the cage, and probably to a greater extent by degradation of the cage chelator biologically both intracellularly and extracellularly, and by radioactive emission breaking down the cage chelator.
[0018] The released toxic cations are then chelated by the orally administered binding agents disclosed herein, such as C2E2. After complexing with the binding agents, the metal-binding agent complex is more easily removed by the kidneys and excreted into the urine, without accumulating in tissue such as bone or salivary glands — thus reducing toxicity to non-target tissues, especially bone marrow, salivary glands, kidneys, and pancreas.
[0019] The compounds of Formula I, including C2E2, are designed to occupy a specific binding-affinity window: they have metal-cation binding affinities (log K) lower than that ofcyclic targeting chelators such as DOTA and macropa-based ligands, but higher than that of endogenous plasma proteins and small-molecule biological ligands such as albumin, transferrin, ferritin, ADP, and ATP. This intermediate affinity window allows the compounds of Formula I to scavenge cationic metals only after those metals have been released from the targeting cage, without stripping intact targeted radionuclide-chelator complexes that are en route to the tumor target. Methods are disclosed for using this affinity- window selectivity to reduce off-target toxicity, including specifically to reduce salivary-gland radiation dose and incidence of xerostomia in patients receiving PSMA-targeted radioligand therapy.
[0020] One embodiment of the invention provides a method of reducing side effects from a medical diagnostic or therapeutic procedure that comprises internal systemic administration of a toxic cationic metal complex: wherein the cationic metal complex comprises a cationic metal with a charge of +2 or more complexed to a chelator and the cationic metal is toxic. The method comprises: orally administering a binding agent of formula I the same day as or 7 or fewer days after the internal administration of the cationic metal complex,
[0021]
[0022] I
[0023] wherein IT” OR:or ---IN HR2;
[0024] R1=same or different and is independently selected from H, C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl or benzyl and at least one R1is not hydrogen; andR2=same or different and is independently selected from C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl. benzyl or phenylalanine ethyl ester.
[0025] One embodiment of the invention provides a method of reducing side effects from a medical therapy comprising internal systemic administration of a targeted cationic radionuclide complex: wherein the targeted cationic radionuclide complex comprises a cationic radionuclide complexed to a chelator; wherein the chelator comprises a targeting moiety that selectively binds to a particular tissue or cell type and the targeted cationic radionuclide complex is targeted to selectively bind to the particular tissue or cell type. The method comprises orally administering a compound of formula I.
[0026] The same binding agents can remove gadolinium that is used in MRI procedures and sometimes causes adverse events including kidney damage, pancreatitis, and neurological symptoms including brain fog.
[0027] Thus, another embodiment of the invention provides a method of reducing side effects from a magnetic resonance imaging procedure that comprises internal administration of gadolinium, the method comprising: orally administering a compound of chemical formula I the same day as or 7 or fewer days after the internal administration of the gadolinium.
[0028] In a further embodiment, the methods are directed to scavenging radioactive daughter isotopes released by nuclear recoil following alpha decay of an alpha-emitting targeted radionuclide complex, where the recoil energy is sufficient to disrupt the chelation of the daughter isotope. In a further embodiment, the methods are practiced in combination with administration of an immune checkpoint inhibitor (for example, an anti-PD-1, anti-PD-Ll, or anti-CTLA-4 antibody) and the orally administered compound of Formula I reduces myelosuppression caused by the radionuclide, thereby preserving immune function during checkpoint inhibitor therapy.
[0029] Another embodiment provides a method of reducing off-target radionuclide toxicity in a patient receiving targeted radioligand therapy, comprising: (a) administering to the patient a targeted cationic radionuclide complex comprising a cationic radionuclide complexed to a targeting chelator that selectively binds a tumor-associated membrane antigen, wherein the targeting chelator has a first dissociation constant (KD-chelator) for the cationic radionuclide at physiological pH; and (b) orally administering to the patient a binding agent of Formula I,as defined above, the same day as or 7 or fewer days after step (a); wherein the binding agent has a second dissociation constant (KD-binding-agent) for the cationic radionuclide at physiological pH that is greater than Ko-chelator and less than the dissociation constant of human serum albumin for the same cationic radionuclide; and wherein the orally administered binding agent scavenges free cationic radionuclide and free radioactive daughter isotopes released in vivo from the targeted cationic radionuclide complex without stripping the cationic radionuclide from the intact targeting chelator.
[0030] Another embodiment provides a method of reducing toxicity from alpha-emitting daughter isotopes in a patient receiving a targeted alpha-emitting radionuclide complex, the method comprising: (a) administering to the patient the targeted alpha-emitting radionuclide complex, wherein the alpha-emitting radionuclide undergoes sequential alpha decay to produce daughter isotopes, and wherein the recoil energy of the alpha emission is sufficient to disrupt the chelation of the daughter isotopes by the targeting chelator and release free daughter isotopes into circulation; and (b) orally administering to the patient a binding agent of formula I as defined above; wherein the compound of Formula I is administered before, at the same time as, or up to 7 days after the administration of the targeted alpha-emitting radionuclide complex and wherein the orally administered binding agent scavenges the released free daughter isotopes in systemic circulation before deposition of those daughter isotopes into bone marrow, kidney, salivary gland, liver, or other non-target tissue.
[0031] Another embodiment provides a method of reducing systemic retention of an internalized radionuclide in a subject following accidental, occupational, or environmental radiological exposure, the method comprising orally administering to the subject a compound of Formula I as defined above; wherein the compound of Formula I is administered within 0 to 7 days after the exposure, in a dose of 250 mg to 1,500 mg, once or twice daily, for 3 to 42 days, thereby reducing soft-tissue and skeletal deposition of the internalized radionuclide.
[0032] Brief Description of the Drawings
[0033] FIG. 1 shows a schematic for synthesis of C2E2.
[0034] FIG. 2 is a binding curve showing the competitive binding for Gadolinium with C2E2 verus albumin.FIG. 3 shows daily gadolinium rate excretion following oral administration for C2E2 to rats. Significance was determined with a two-way A NOVA followed by multiple t-test with Bonferroni correction for multiple comparisons. * p > 0.05; ** p > 0.01; *** p > 0.001.
[0035] FIG. 4 shows daily gadolinium excretion rate in rats normalized by urine mass following oral administration of C2E2 and i.v. administration of Zn-DTPA. Lines represent the best fit using simple linear regression. Significance was determined with a mixed methods ANO VA followed by multiple t-test with Bonferroni correction for multiple comparisons where no individual treatments were found to be significantly different on any day. * p < 0.05.
[0036] FIG. 5 shows the plasma concentrations of C2E2, C2E1 and DTPA after administration of 100-mg per kg C2E2 as oral solution. The effective duration based on EC50 and EC90 values are indicated by dotted lines.
[0037] Detailed Description
[0038] The problem: For radioligand diagnostic / therapeutic agents the radioactive isotope or radioactive or toxic cationic metal radioactive decay products deposit in non-target healthy tissues, such as kidneys, liver, bone, bone marrow, and salivary glands. For beta emitters, such as Lu- 177, Y-90, Cu-67, and 161Tb, this happens mostly because of metabolic degradation of the DOTA moiety, the linker, or the target binding domain of the agent. Free metal is released in circulation or in tissue and then expelled from the tissue into circulation.
[0039] For alpha emitters, such as Ac-225, Th-227, Ra-223, and Pb-212 (which decays through alpha-emitting Bi-212 / Po-212), radioactive or toxic cationic radioactive decay products are released from the diagnostic / therapeutic agents primarily following high-energy alpha emission. The recoil energy of the emitted alpha particle (typically 100-200 keV imparted to the daughter nucleus) is sufficient to break chemical bonds in the chelator moiety, the linker, or the target binding domain of the agent, causing release of free toxic cation and free radioactive daughter isotopes into circulation or tissue.
[0040] PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is a targeted radioligand therapeutic for treatment of prostate cancer. It is a radioactive diagnostic / therapeutic agent (theranostic), used to treat pro state- specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. Despite high chelation stability at the time of administration, clinically meaningful off-target radiation exposure occurs over the course oftreatment. This is not a failure of targeting — it reflects the metabolic degradation and biological clearance of radioligand therapies in vivo. Free radionuclides generated through metabolic dechelation circulate systemically and deposit in sensitive tissues — including kidneys, bone marrow, and salivary glands — prior to elimination.
[0041] C2E2 and the related agents of Formula I described herein operate in the blood pool, scavenging and binding free radionuclides and toxic cationic decay products before organ deposition. Importantly C2E2 and the related agents of Formula I have affinity constants lower than DOTA, so they cannot strip the therapeutic / diagnostic radionuclide from the DOTA ring or the therapeutic / diagnostic agent. And they have affinity constants higher than the biological binding proteins and compounds found in blood, such as albumin, ferritin, transferrin, and ADP and ATP, so they outcompete those biological compounds for the toxic cation. Thus, they are able to bind toxic cations and keep them in circulation and away from non-target tissues. They then efficiently move them to the kidneys where the chelated cation complex with the compound of formula I is filtered and removed safely from the body in urine.
[0042] The log K hierarchy with Lu is DOTA-Lu 25.4 > C2E2-Lu -19.6 > plasma proteins less than 15. C2E2's binding affinity for Lu thus falls into a window strictly lower than the DOTA cage of the targeted therapeutic radionuclide complex and strictly higher than the binding affinity of plasma proteins and other endogenous biological ligands. As a result, C2E2 cannot strip lutetium from an intact 177Lu-DOTA targeted complex, but readily out-competes albumin, transferrin, ferritin, ADP, and ATP for any free Lu3+ released into circulation by metabolic dechelation, kinetic equilibrium, or radiation-induced damage to the chelator. The same hierarchy holds, with comparable margins, for the other toxic and radioactive cations enumerated herein, including Ac3+, Bi3+, Pb2+, Y3+, Sm3+, Gd3+, and the lanthanide and actinide series generally. The compounds of Formula I therefore occupy a generalizable affinity window between targeting chelators and endogenous biological ligands for any toxic or radioactive cation having a charge of +2 or greater.
[0043] C2E2 and the related compounds of Formula I, by reducing adverse events, increase the therapeutic window, allowing a higher dose of the targeted therapeutic radionuclide to be used for better effect with the same or lower side-effects and adverse events. The use of thechelators of Formula I in conjunction with a targeted therapeutic radionuclide also allows expansion of the patient population to patients with earlier stage cancers. In patients with earlier stage cancers, physicians are less willing to risk adverse events, because the patients have a higher quality of life, a longer life expecancy, and greater likelihood of survival. By reducing the side effects and adverse events associated with targeted therapeutic radionuclides, C2E2 and the compounds of formula I improve the benefit-to-risk ratio of use of targeted therapeutic radionuclides to allow their use in patients with earlier stage and less serious cancers and in patients with compromised renal function, low baseline blood counts or other conditions that would make them poor candidates for therapeutic radionuclide therapy in the absence of the compounds of formula I that can reduce the toxicity of the therapy.
[0044] In the VISION trial, the pivotal Phase 3 clinical trial report for Lutetium- 177-PSMA-617 (Sartor, O. et al. Lutetium- 177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Mecl 2021; 385: 1091- 103) more than 50% of patients in the PLUVICTO® arm experienced Grade >3 adverse events, with toxicity contributing to dose delays, reductions, and early discontinuation. These constraints will become more consequential as the field moves toward earlier-line use, combination strategies, and next- generation alphaemitting programs. C2E2 and related compounds of Formula I can reduce these adverse events.
[0045] Methods are provided herein for reducing off-target radiation exposure in a patient receiving internally administered radiolabeled therapy for cancer targeted to a specific cell target or cell type, including but not limited to prostate-specific membrane antigen (PSMA)-targeted agents such as PLUVICTO®.
[0046] The methods can be used to reduce side effects from targeted radionuclide therapy involving any radinuclide, including but not limited to:
[0047] o Lutetium- 177
[0048] o Actinium-225
[0049] o Actinium-227
[0050] o Samarium- 153
[0051] o Yttrium- 90
[0052] o Other medically relevant beta, alpha, or Auger-emitting isotopesThe binding agents in the methods chelate not only residual unbound therapeutic radionuclides but also their radioactive and non-radioactive daughter products and impurities, including but not limited to:
[0053] o Ac-225 decay products: Bi-213, Fr-221, Po-213, Pb-209, Tl-209
[0054] o Lu- 177 impurities: Lu- 177m, and trace lanthanide contaminants
[0055] o Other isotopic impurities and dissociated radiometals from Sm-153, Y-90, or Gd-based imaging agents
[0056] This reduces uptake and retention of these toxic products in non-target tissues.
[0057] One embodiment provides a method of reducing side effects from a medical diagnostic or therapeutic procedure that comprises internal systemic administration of a toxic cationic metal complex, wherein the cationic metal complex comprises a cationic metal with a charge of +2 or more complexed to a chelator and the cationic metal is toxic. The method comprises orally administering a binding agent of formula I the same day as or 7 or fewer days after the internal administration of the cationic metal complex,
[0058]
[0059] I
[0060] wherein R=—OR1or —NHR2;
[0061] R1=same or different and is independently selected from H, C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl or benzyl and at least one R1is not hydrogen; and
[0062] R2=same or different and is independently selected from C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl, benzyl or phenylalanine ethyl ester.In specific embodiments of the compounds of formula I, R=OR1and R1=same or different and is independently selected from C1-C6 alkyl and H and at least one R1is C1-C6 alkyl.
[0063] In other embodiments, R=OR1and two R1are C1 -C6 alkyl and two R1are H.
[0064] In a specific embodiment, the compound of formula I is C2E2.
[0065]
[0066] C2E2
[0067] In specific embodiments, the step of orally administering the compound of formula I reduces tissue accumulation of the cationic metal, which may be a radionuclide, a toxic byproduct of radioactive decay of a radionuclide, or it may be gadolinium.
[0068] In a specific embodiment, the step of orally administering the compound of formula I reduces accumulation of the radionuclide or other toxic metal in bone.
[0069] In a specific embodiment, the step of orally administering the compound of formula I reduces incidence of myelosuppression (for example, lymphopenia, neutropenia, or anemia, or a combination thereof).
[0070] In a specific embodiment the step of orally administering the compound of formula I reduces deposition of the toxic metal in bone or liver.
[0071] In a specific embodiment, the step of orally administering the compound of formula I reduces at least one of liver damage, kidney damage, pancreatitis, and neurological symptoms.
[0072] In specific embodiments of the methods, the methods involve administering the compound of formula 1 (for example, C2E2) at a dose of 250 mg to 1500 mg twice daily for 3 to 14 days after each dosing of the radioisotope or toxic cation. In other embodiments, themethods involve administering the compound of formula I at a dose of 250 mg to 2,000 mg once or twice daily for 3 to 42 days after each dosing of radioisotope or toxic cation; or 500 to 1500 mg once or twice daily for 3 to 42 days. Typically, the compound of formula I is administered twice daily.
[0073] The timing and the duration of administration of the binding agent compound of formula I depends on the decay time of the radionuclide and on the in vivo elimination halflife of the radionuclide, toxic radionuclide decay product, or gadolinium, and the absorption time and elimination half-life of the compound of formula I. In specific embodiments, one can administer the compound of formula I for at least 2 to 6 elimination half-lives of the toxic cation. PLUVICTO® has an elimination half-life in urine of about 7 days. So with PLUVICTO® in one embodiment the compound of formula I is administered for 14 to 42 days.
[0074] It may also be advisable to administer the compound of formula I (e.g. C2E2) before or at the same time as the radionuclide or toxic cationic metal complex is administered, so that it is in the blood and can immediately bind to toxic cationic metal that is released before it can do any damage. This may be advisable when the binding agent has a higher dissociation constant (KD) than the targeting chelator-i.e., the binding agent binds to the cationic radionuclide or other toxic cationic metal less tightly than the targeting chelator. In that case, the binding agent is not expected to interfere with the intended effect of the targeted radionuclide or toxic cationic metal chelator complex because it will not significantly extract the radionuclide or toxic cation from its cage. But when the radionuclide or toxic cation is released from its cage (its chelator) — either because of simple kinetic equilibrium, or biological degradation of the chelator, either intracellularly or extracellularly, or because the chelator is damaged by radiation from the radioisotope — the binding agent will be available to bind the radionuclide or its toxic decay products or toxic cation and facilitate excretion of them in the urine or feces before they can accumulate in non-target tissue or cause damage to non-target tissues.
[0075] The compounds of formula I have higher dissociation constants (KDS) (i.e., lower binding constants) than the cyclic chelators with 4 or more electronegative atoms or groups that bind the toxic metal cation. And they should have lower dissociation constants (higher binding constants) than serum albumin and other biological compounds in blood and in tissuethat bind to the toxic cations, so that the binding agents can outcompete non-target tissue for the toxic cations and thus capture the toxic cations for removal from the body before they have bound to non-target tissue, or can strip toxic cations that have bound to non-target tissue.
[0076] Thus, in some embodiments, the binding agent has a log KD (i.e., log base 10) for the cationic toxic metal at physiological pH that is at least 1 log unit higher than the log KD of the targeting chelator and at least 1 log unit lower than the log KD of human serum albumin for the same toxic cation. In other embodiments, the binding agent has a log KD for the cationic toxic metal at physiological pH that is at least 2 log units higher than the log KD of the targeting chelator and at least 2 log units lower than the log KD of human serum albumin for the same toxic cation.
[0077] In specific embodiments, the method comprises administering the compound of formula I (for instance C2E2) before the toxic cationic metal complex is administered, for instance, 0 to 24 hours before or 0 to 6 hours, or 6 to 24 hours before the toxic cationic metal complex is administered.
[0078] In other embodiments, the compound of formula I (for instance C2E2) is administered shortly after the toxic cationic metal complex is administered, e.g., 0 to 3 hours after or 0 to 6 hours after the toxic cationic metal complex is administered.
[0079] In other embodiments, the method comprises administering the compound of formula I (for instance C2E2) 6 to 24 hours after or 24 to 72 hours after the toxic cationic metal complex is administered.
[0080] In other embodiments, the method comprises administering the compound of formula I (for instance C2E2) at least once daily starting from 1 day before to up to 3 days after the toxic cationic metal complex is administered and ending at 7 to 42 days (or 2 to 6 elimination half-life periods of the toxic cationic metal) after the toxic cationic metal complex is administered.
[0081] It may also be advisable to allow time for the binding agent to clear the system before second and subsequent administrations of the targeted cationic radionuclide complex. Thus, in specific embodiments, the method does not comprise administering the compound of formula I (for instance C2E2) in days 1, 2, and 3 immediately prior to a day that the toxic cationic metal complex is administered.Tn another specific embodiment, the method does not comprise administering the compound of formula I (for instance C2E2) in days 1, 2, and 3 immediately prior to the day that a second or subsequent dose of the targeted cationic radionuclide complex or other toxic cationic metal complex is administered.
[0082] In specific embodiments, the chelator comprises a cyclic ring and comprises at least 4 electronegative atoms or groups that bind the cationic radionuclide.
[0083] In specific embodiments, the chelator comprises a 1,4,7, 10-tetraazacyclododecane ring or a diaza- 18-crown-6 macrocycle ring.
[0084] In specific embodiments, the chelator is PSMA-617.
[0085] In specific embodiments, the binding agent has a higher dissociation constant (KD) than the chelator at physiological pH in aqueous solution.
[0086] In specific embodiments, the binding agent has a KD at least 4-fold higher, at least 10-fold higher, or at least 30-fold higher than the chelator.
[0087] In specific embodiments, the targeted cationic radionuclide complex is177Lu-PSMA-617.
[0088] In specific embodiments, the radionuclide is an isotope of lutetium, actinium, lead, gallium, samarium, yttrium, thorium, bismuth, or a combination thereof.
[0089] In specific embodiments, the radionuclide is selected from the group consisting of Lu-177, Ac-225, Ac-227, Pb-212, Ga-68, Y-90, Sm-153, and Ra-223, and combinations thereof.
[0090] In specific embodiments, the radionuclide is selected from the group consisting of Lu-177 and Ac-225, and Ac-227, and combinations thereof.
[0091] In specific embodiments, the radionuclide is selected from the group consisting of Pb-212, Ga-68, Y-90, Sm-153, and Ra-223.
[0092] In specific embodiments, the radionuclide therapy is administered in combination with an immune checkpoint inhibitor selected from anti-PD-1, anti-PD-Ll. or anti-CTLA-4 antibodies. The binding agents, since they reduce myelosuppression, have the advantage that they reduce the interference of the targeted radiotherapy with immune action against cancer cells.
[0093] In specific embodiments of the methods, the method comprises administering the compound of formula I (for instance C2E2) at least once daily starting from 1 day before to up to 3 days after the targeted cationic radionuclide complex (or other toxic cationic metalcomplex) is administered and ending at 7 to 42 days (or 2 to 6 elimination half-life periods of the toxic cationic metal complex) after the toxic cationic metal complex is administered.
[0094] Another embodiment provides a method of reducing side effects from a medical resonance imaging procedure that comprises internal administration of gadolinium, the method comprising:
[0095] orally administering a compound of chemical formula I the same day as or 7 or fewer days after the internal administration of the gadolinium
[0096]
[0097] I
[0098] wherein R=—OR1or —NHR2;
[0099] R1=same or different and is independently selected from H, C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl or benzyl and at least one R1is not hydrogen; and
[0100] R2=same or different and is independently selected from C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl, benzyl or phenylalanine ethyl ester.
[0101] In specific embodiments, R=OR1and R’=same or different and is independently selected from Ci-Ce alkyl. In more specific embodiments, the compound of chemical formula I is C2E2.Tn specific embodiments, the method step of orally administering the compound of formula 1 (for instance C2E2) occurs within 0 to 24 hours after completion of the MRI procedure.
[0102] In some embodiments of the methods of reducing toxicity from gadolinium in MRI the compound of formula I is administered daily (preferably once or twice daily) on the day of the MRI procedure and for 2 to 7 days after the procedure.
[0103] In one embodiment the targeted cationic radionuclide complex is administered in combination with an immune checkpoint inhibitor selected from the group consisting of an anti-PD-1 antibody, an anti-PD-Ll antibody, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-TIGIT antibody, and combinations thereof, wherein the orally administered compound of Formula I reduces myelosuppression caused by the radionuclide, thereby preserving immune function during checkpoint inhibitor therapy.
[0104] In a more specific embodiment, the immune checkpoint inhibitor is pembrolizumab, nivolumab, atezolizumab, durvalumab. or ipilimumab.
[0105] In one embodiment of the inventions involving a targeted cationic radionuclide complex, the radionuclide is Pb-212, and the orally administered compound of Formula I chelates free Pb-212 and its decay daughter isotopes Bi-212, Po-212, and Tl-208 generated by metabolic dechelation, kinetic dissociation, or alpha-recoil release from the targeted Pb-212 complex.
[0106] In one embodiment of the methods, the targeted cationic radionuclide complex is administered in two or more sequential cycles, and the compound of Formula I is administered orally beginning within 24 hours of each cycle and continuing at least once daily for 7 to 42 days after each cycle, and wherein the compound of Formula I is not administered during the 1 to 3 days immediately preceding each subsequent cycle of the targeted cationic radionuclide complex.
[0107] In one embodiment of the methods involving administration of a targeted cationic radionuclide complex, the orally administered compound of Formula I reduces salivary-gland radiation dose and the incidence and severity of xerostomia in the patient as compared to administration of the targeted cationic radionuclide complex without the compound of Formula I.Tn specific embodiments of the methods, the compound of Formula I has a Caco-2 monolayer permeability (Papp) at least 5 -fold higher than the Papp of diethylenetriaminepentaacetic acid (DTPA) measured under the same assay conditions.
[0108] In specific embodiments of the methods, the compound of Formula I has an absolute oral bioavailability of at least 15% in a mammalian subject.
[0109] In specific embodiments of the methods, the compound of Formula I is administered without a permeation enhancer.
[0110] In specific embodiments of the methods involving administration of a targeted toxic cation or radionuclide, the the targeting chelator targets a tumor- associated membrane antigen selected from the group consisting of prostate- specific membrane antigen (PSMA), somatostatin receptor 2 (SSTR2), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), fibroblast activation protein (FAP), CD20, CD33, CD38, gastrin-releasing peptide receptor (GRPR), carbonic anhydrase IX (CAIX), and combinations thereof.
[0111] In more specific embodiments, the targeting moiety is PSMA-617, DOTATATE, DOTATOC, FAPI-46, FAPI-04, or trastuzumab.
[0112] In specific embodiments involving administration of a targeted cationic radionuclide, the compound of Formula I is administered orally beginning 1 to 7 days prior to the administration of the targeted cationic radionuclide complex and continuing for 7 to 42 days after each administration of the targeted cationic radionuclide complex.
[0113] In specific embodiments of the methods involving administration of a targeted cationic radionuclide to a patient, the patient has Stage I, Stage II, or Stage III cancer at the time of administration of the targeted cationic radionuclide complex, or has compromised baseline renal function, baseline neutrophil count, baseline platelet count, or baseline hemoglobin that would otherwise contraindicate administration of the targeted cationic radionuclide complex.
[0114] In specific embodiments of the methods described herein, the compound of Formula I is administered as an oral capsule, oral tablet, or oral solution, in fasted condition.
[0115] Examples
[0116] Methods to prepare the compounds of formula I are described in U. S. Patent No. 9,546,129, which is incorporated by reference.Example 1. Methods for preparing C2E2
[0117] Method 1 for Preparing C2E2
[0118] The first step in Method 1 for preparing C2E2 (also known as 6,9-bis(carboxymethyl)-3-(2-ethoxy-2-oxoethyl)-l l-oxo-12-oxa-3,6,9-triazatetradecan-l-oic acid) comprises providing DTPA bis-anhydride. DTPA bis-anhydride is commercially available and may be obtained from commercial suppliers, such as TCI America of Portland, Oreg., or may be prepared as follows.
[0119] Preparation of Bis-anhydride
[0120] Step 1 — DTPA (3.93 g, 10 mmol) and acetic anhydride (5.72 g, 56.9 mmol) were added to 6.2 mL of pyridine and heated to reflux 65-70° C. for 14 hours. The material was filtered through a Buchner funnel and rinsed with diethyl ether. An off-white powder (DTPA-BA, 1) was collected and dried in a desiccator.1HNMR (400 MHz, DMSO) δ3.65 (8H, s), 3.44 (2H, d), 2.74 (4H, t), 2.59 (4H, t).
[0121]
[0122] Once DTPA bis-anhydride is obtained, Step 2 is followed to prepare C2E2.
[0123] Preparation of C2E2
[0124] Step 2 — DTPA-BA (1) is used to produce C2E2 (2) by reacting DTPA-BA (1) with ethanol. DTPA-BA (1.02 g, 2.8 mmol), ethanol (0.38 g, 8.2 mmol) and pyridine (0.67 g, 8.4 mmol) were stirred under nitrogen for 24 hours. The product was precipitated in dichloromethane (DCM) (200 mL) at -20° C., filtered while washing with DCM, and dried in a vacuum oven to give an off-white powder (Yield — 81.3+13.3, n=4).1HNMR (400 MHz, DMSO) δ4.07 (4H, q), 3.53 (4H, s), 3.45 (2H, s), 3.43 (4H, s), 2.89 (4H, d), 2.84 (4H, d), 1.19 (6H, t). Elemental analysis: Predicted — C, 48.10; H, 6.95; N, 9.35; O, 35.60; Actual — C,47.59; H, 7.22; N, 8.67; 0, 36.29. The synthesis of C2E2 has also been successfully prepared
[0125]
[0126] Method 2 for Preparing C2E2
[0127] According to Method 2 for preparing C2E2, C2E2 was manufactured on a 1.5 kg scale according to the synthetic scheme in FIG. 1. The synthesis of bis-anhydride 2 from DTPA (1) is described in European Application No. EP136134A1 (2003), International Publication No. WO 2007 / 142804 A2, and Chemistry, A European Journal, 2004, 10, 3252-3260, the contents of each of which are incorporated herein by reference in their entirely for the teachings relevant to this paragraph. In each case the penta-acetic acid was treated with acetic anhydride and pyridine either neat or in the presence of MeCN and the yield range observed was 95-91%. The bis-anhydride is then converted to C2E2 by reaction with ethanol. This conversion has been used to prepare 800 g as well as 1.5 kg of C2E2.
[0128] Preparation of Bis-anhydride (2):
[0129] Diethylenetriamine pentaacetic acid (2029 g, 5.16 mole) was dissolved in acetonitrile (1100 m ) with agitation. Acetic anhydride (1450 mL, 15.3 mole) and pyridine (1660 ml, 20.5 mole) were added and the reaction was heated to 60° C. for 4 hours. The reaction mixture was cooled to 22° C. and t-butylmethylether (MTBE) (800 mL) was added. The reaction mixture was filtered and the solid obtained was washed with MTBE (3000 mL). The solid was dried in a vacuum oven at 40° C. Yield: 1792 g, 97%.
[0130] Preparation of C2E2:
[0131] The bis-anhydride (1792 g, 5.02 mole) was slurried in absolute ethanol (9000 mL) and heated to reflux with agitation for 1.5 hour. The heated reaction mixture was filtered through Celite and cooled below 20° C. The resulting slurry was filtered and washed with cold ethanol (2800 mL) followed by methyl tert-butyl ether (MTBE) (3500 mL). The Celite cake was slurried in ethanol (800 mL) and heated to 70° C. and filtered. On cooling, the slurry obtained was filtered and washed with ethanol and MTBE. The combined isolated solids were dried in a vacuum oven at room temperature. Yield: 1488 g, 66%.
[0132] Therapeutic Use Examples
[0133] Example 2: A patient receives Lu-177-PSMA-617 for metastatic prostate cancer. Beginning at 0 to 48 hours post-infusion, the patient is administered C2E2 (or another compound of Formula I) at a dose of 250 mg to 1,500 mg, orally, once or twice daily, for a duration of 3 to 42 days following each Lu-177-PSMA-617 administration cycle. In a representative regimen, the patient receives 500 mg of C2E2 twice daily for 14 days following each cycle of Lu-177-PSMA-617. The C2E2 chelates residual circulating Lu- 177 and reduces renal-tubular and salivary-gland uptake of free 177Lu3+ generated by metabolic dechelation, thereby reducing nephrotoxicity, salivary- gland toxicity, and bone-marrow toxicity associated with the radioligand therapyExample 3: Example 3: A patient receives Ac-225-PSMA-617 therapy. At 24 hours post-infusion, C2E2 is administered orally to chelate circulating Bi-213 and other Ac-225 decay products having half-lives sufficient to permit therapeutic intervention (including Pb-209 and Tl-209), thereby reducing bone marrow and renal exposure to alpha and beta emissions. The patient continues to receive C2E2 dosed up to twice daily for up to 42 days following the Ac-225-PSMA-617 infusion.
[0134] Example 4: A patient receives radioligand therapy containing a chelated Actinium-225 compound. Following the decay of Ac-225, daughter radionuclides — including Bi-213 (and shorter-lived intermediate Po-213 and At-217), Pb-209, and Tl-209 — are released by nuclear recoil energy of the alpha decay, which is sufficient to disrupt the coordination chemistry of the parent chelator. The released cationic daughters become systemically distributed. Bismuth ions preferentially accumulate in the proximal tubules of the kidney; lead-containing decay products may additionally substitute for calcium in hydroxyapatite of bone and contribute to long-term skeletal radiation burden. At 36 hours post-therapy. C2E2 is administered orally in a dose of 250 to 1500 mg to chelate these circulating and tissue-deposited decay products. The chelated complex is preferentially excreted in urine, reducing renal-tubular and bone marrow toxicity and lowering long-term radiological burden in metabolically active tissues. C2E2 administered in this way enhances systemic clearance of alpha-emitting daughters and lowers cumulative organ dose
[0135] Example 5: A patient receives a radiotherapeutic compound containing Actinium-227, either as part of a therapeutic regimen or as a production impurity in other actinium-based treatments. Due to its longer half-life and the potential for incomplete chelation, a portion of the administered Actinium-227 remains unbound and circulates freely in the bloodstream. At time points greater than 36 hours post-administration, unbound Ac-227 begins to deposit in tissues such as bone and soft tissue due to its chemical similarity to calcium and phosphate. To mitigate off-target deposition and potential marrow or organ toxicity, an oral doses of C2E2 are administered to chelate circulating and tissue-deposited Ac-227, promoting its systemic clearance and reducing cumulative radiotoxic burden.
[0136] Example 6: A patient receives Ac-225-PSMA-617 therapy. As with other alphaemitting therapies, unbound daughter radionuclides such as Bi-213 and Fr-221 circulate and may deposit in renal tissues, particularly within the proximal tubules. Beginning at 36 hourspost-infusion, the patient is administered oral doses of C2E2 twice per day for 10 days. The C2E2 binds circulating ions and reduces their uptake in the kidneys, protecting the renal tubules and lowering the overall burden of radiation-induced nephrotoxicity.
[0137] Example 7: A patient undergoes radioligand therapy over multiple treatment cycles using radiolabeled compounds such as Actinium-225, Lutetium-177, or Samarium-153. After each cycle, oral C2E2 is administered at 48 and 72 hours post-treatment to chelate both circulating parent radionuclides and their decay products. This repeat dosing protocol minimizes cumulative radiation exposure and supports safe continuation of therapy by reducing marrow and renal toxicity.
[0138] Example 8: A healthcare worker exposed, known or suspected to have received radiological exposure, receives a therapeutic chelator as emergency decorporation. An oral DTPA prodrug such as C2E2 is administered within 48 hours to reduce systemic retention and mitigate soft tissue and skeletal deposition.
[0139] Example 9: A patient with metastatic bone pain from prostate cancer receives Samarium-153 lexidronam, a radiopharmaceutical that accumulates in areas of high bone turnover. After radiopharmaceutical binding, a portion of unbound Sm-153 remains in systemic circulation and is excreted renally. At 8 hours post-administration, an oral DTPA diethyl ester is given to chelate the remaining Sm-153 and reduce renal exposure and radiation burden to non-target tissues.
[0140] Example 10: A patient receives Yttrium-90 microsphere therapy (e.g., THERASPHERE® or SIR-SPHERES®) for hepatocellular carcinoma. Although the microspheres are designed to localize in hepatic vasculature, a small amount of Y-90 may remain unbound or dissociate into systemic circulation. At 6 to 12 hours post-administration, an oral DTPA diethyl ester is administered to chelate residual Y-90 ions and reduce deposition in bone and renal tissues. This helps lower off-target beta radiation exposure and supports renal protection during radiotherapy.
[0141] Example 11: A patient with metastatic prostate cancer is treated with Lu-177-PSMA-617 in combination with pembrolizumab (KEYTRUDA®), an anti-PD-1 immune checkpoint inhibitor. At 8 hours post-radiopharmaceutical administration, an oral DTPA diethyl ester is administered to chelate circulating Lu- 177 and reduce renal and marrow exposure. Thisenables continued immunotherapy while mitigating radiation-induced toxicity that could suppress systemic immune activation.
[0142] Animal and In Vitro Examples
[0143] Example 12. Removing Am-241 in a rat wound model.
[0144] Am-241 was administered topically to rat wounds.
[0145] After a single dose of C2E2, dose-dependent 241Am decorporation was observed at a C2E2 oral dose of 200, 600, 1000 mg / kg. Efficacy at 1000 mg / kg approached IV Ca-DTPA (gold standard). Concomitant reductions in liver and skeletal burden of Am-241 were confirmed.
[0146] Both QD (600 mg / kg) and BID (300 mg / kg) regimens similarly increased decorporation and reduced liver / skeletal burden. So efficacy depends on total exposure (AUC), not Cmax.
[0147] With a 7-day repeat dose of C2E2 there was dose-related increase in renal elimination of 241Am and decrease in liver burden at 200 mg / kg. Treatment was initiated 24 hours postcontamination.
[0148] 5 vs 10-day dosing of C2E2 was compared. There was a clear benefit of continued treatment beyond 5 days. Each additional dose increased 24-hour urinary 241Am excretion vs. controls. So efficacy is cumulative.
[0149] Example 13. Toxic cation removal in a beagle dog inhalation model.
[0150] A single dose of 241Am was given to beagle dogs by inhalation. Dogs were then dosed orally with C2E2. A dose-dependent increase in Am-241 decorporation was observed at at 100, 300, 500 mg / kg. High-dose group: >65% decrease in liver / spleen, >50% decrease in kidney / lung / GIT, >30% decrease in total bone content. An up to 13-fold urinary elimination increase compared to the baseline with no C2E2 was observed.
[0151] A single dose of 239Pu was administered by inhalation. Oral C2E2 successfully evaluated vs. Plutonium-239 inhalation. Cumulative urinary elimination of 239Pu after oral C2E2 dosing was statistically significant compared to undosed controls — demonstrating broad-spectrum transuranic coverage beyond americium.Example 14. Rat lead contamination model — 7-day repeated dose (Pb) C2E2 dose (250 mg / kg vs 500 mg / kg) and administration frequency (QD vs. BID) dependent Pb removal from kidney and liver was observed in rats fed Pb in drinking water for 9 weeks prior to the start of treatment. These data indicate Pb decorporation efficacy, supporting C2E2’s ability to remove 212Pb during radioligand therapy.
[0152] Example 15. Oral bioavailability
[0153] C2E2 was given orally to rats. 29% of dosed C2E2 was detected in plasma in rats (absolute). Food reduced the exposure ~8-fold in dogs — clinical protocol uses fasted dosing.
[0154] Tmax is 0.25h (rat) / 0.5-2h (dog). This is rapid absorption and it enables a timely post-RLT administration window.
[0155] Terminal half-life (t1 / 2) is ~1h (rat IV), 3-5h (dog oral). No accumulation after 28 days of repeat dosing was observed in either species.
[0156] Distribution. Vd 0.8 L / kg (rat IV). Protein binding: 82.9-94.0% of C2E2 is free (human plasma), which means a high free fraction available for chelation.
[0157] Metabolism. Sequential ester hydrolysis of C2E2 to C2E1 and DTPA could occur. But we observed that the parent C2E2 remains predominant circulating species (<3.5% metabolite exposure). No reactive metabolites were found.
[0158] Caco-2 permeability. Caco-2 permeability is ~10x higher than DTPA — confirms oral absorption mechanism is driven by enhanced membrane permeability.
[0159] Conclusion: C2E2 is substantially absorbed into blood from oral administration and about 10-fold more bioavailable orally than DTPA. C2E2 is thus suitable for oral dosing to reduced toxicity of radioligand therapy.
[0160] Example 16. Toxicology.
[0161] Single-dose MTD (Maximum Tolerated Dose)
[0162] Rat: 2000 mg / kg I Dog: 750 mg / kg
[0163] Both well-tolerated clinically at maximum dose levels
[0164] 28-day GLP study in rats (NOAEL) (No Adverse Event Level)400 mg / kg / day — target organs GI tract and kidney at higher doses; effects reversible at NOAEL
[0165] 28-day GLP dog (NOAEL)
[0166] No adverse events in dogs were observed at 80 mg / kg / day — human equivalent dose estimated at ~3g / day, well above projected therapeutic dose
[0167] Genotoxicity (3 GLP assays)
[0168] C2E2 was negative for genotoxicity in assays of: Ames bacterial reverse mutation, chromosomal aberration (CHO cells), and bone marrow micronucleus in rats
[0169] CYP (Cytochrome P450) inhibition (8 isoforms)
[0170] No inhibition of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, or 3A5 by C2E2 was observed at concentrations up to 100 μM.
[0171] Example 17
[0172] Determining the C2E2 concentration required to bind 90% of the free Gd3+ ions in human plasma within 30 minutes, and calculate the affinity binding constant of C2E2 for Gd.
[0173] The ability of C2E2 to chelate Gd in blood was investigated by in vitro experimentation
[0174] using a method developed in our lab. Various concentrations of chelating ligand were combined with Gd in human plasma before separation and evaluation. All samples utilized 393 μL of plasma and 7 μL of Gd solution. The ligand was directly dissolved in human plasma to final concentrations ranging from 0.5 to 500 μM. The Gd stock solution was prepared by dissolving GdCh in water. The resulting concentration of Gd after addition to the plasma samples containing the ligand was 0.5 mM.
[0175] The samples were subsequently incubated for 60 minutes in a heating block at 37°C with mild agitation before being transferred to an Amicon Ultra centrifugal filter with an Ultracel 3K membrane (Millipore, Billerica, MA) and centrifuged at 14,000 x g for 30 min to extract the protein-bound fraction. The filtrates were subsequently transferred to Pierce Strong Cation Exchange Spin Columns (Thermo Fisher Scientific, Rockford, IL) that had been conditioned with 0.8 M ammonium hydroxide and water to separate positively charged Gd species from ligand-bound Gd. Elution of the ligand-bound Gd was achieved bycentrifuging at 2000 x g for 5 min. The positively charged Gd species were collected by further centrifugation at 2000 x g with 1 M nitric acid. For analysis, the plasma fraction was digested in 800 μL of 70% HNO3. The Gd content of each fraction was determined by ICP-MS.
[0176] The dose-response curves were produced by calculating the fraction of total Gd that was bound to C2E2 or plasma proteins. The sigmoidal regression profiles were generated by Gauss-Newton non-linear least squares regression analysis using GraphPad Prism 5.01 (GraphPad, La Jolla, CA). The regression applied the Hill equation;
[0177]
[0178] where h describes the slope as the curve approaches the asymptote, Kd is the inflection point, Bmax is the upper asymptote, c is the lower asymptote, and x is the concentration of C2E2 that corresponds to y. the fraction of bound Gd. The EC50 values were determined by setting y equal to the average of c and Bmax. The same regression analysis was applied to the data for Gd-protein binding; however, a transformation was applied to yprotein such that,
[0179] y — 100—J / protein
[0180] where y’ was used for the regression analysis. Subsequent reversal of the transformation produced the final binding curves (Figure 1). The parameters used in the Hill equation as well as the calculated EC50 and EC90 values were as follows in the following Table and in FIG. 2:
[0181]
[0182] Note that a very high (non-physiologic) concentration of Gd (0.5 mM) was used in these
[0183] studies for ease of analysis which led to high EC50 and EC90 values. Similar studies were conducted with 0.5 pM Gd concentrations, but issues with the sensitivity of analysis produced results that were too variable. These studies are being repeated and are expected to produce EC50 and EC90 values of C2E2 1000-fold lower which would be inthe measured plasma concentration range of C2E2 after oral administration.
[0184] Example 18
[0185] Assessing the ability of orally administered C2E2 to prevent deposition of Gd
[0186] in bone when administered prior to gadolinium-based contrast agents (GBCAs) and to reduce bone content of Gd when administered after GBCAs.
[0187] In these experiments, the linear GBCA agent Gadodiamide was administered intravenously to rats at a dose of 0.1 mmol / kg every day for 2 weeks. After a 2-day washout period, a single dose of C2E2 (600 mg / kg) or placebo control was administered orally. Urine was collected daily for the next 5 days, and Gd content in 24-hour urine samples was determined using ICP-MS. The results appear in FIG. 3.
[0188] This was followed by a second study in which animals were administered gadodiamide (0.1 mmol / kg) followed by a rest period and subsequent treatment with oral C2E2 or i.v. DTPA. The results of the Gd assay (ICP-MS) of the urine collections appear in FIG. 4. These results show that the urinary gadolinium excretion of rats that had been administered ten doses of gadodiamide was significantly enhanced following a washout period and subsequent treatment with orallyadministered C2E2 and intravenously administered Zn-DTPA. The tissue samples from these studies are being processed and will be reported at a later time.
[0189] Example 19
[0190] Assessing Pharmacokinetics and Absolute Bioavailability of Orally Administered C2E2.
[0191] To investigate the pharmacokinetics of C2E2 and its metabolites and determine the fraction absorbed, an additional single dose-pharmacokinetic study was performed in Male Sprague Dawley rats using14C-C2E2 that we synthesized in our lab. Jugular- and portal-cannulated Sprague-Dawley rats (263-298 g; n = 3 per time point) were divided into four groups: single IV dose of C2E2 (16.9 mg / kg; jugular or portal vein) to fasted or ad lib rats, or single oral dose of C2E2 (600 mg / kg) or placebo (water) to fasted or ad lib rats. Blood was collected from the jugular catheter (0.7 mL per draw) at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h post dose and immediately transferred to chilled vacutainer tubes containing 5 mg sodium fluoride and 4 mg potassium oxalate. These tubes were inverted to ensure proper mixing andplaced on ice until centrifugation. Tubes were centrifuged at 1,300 x g for 10 minutes at 4°C within 5 minutes of collection. Urine was collected at 2, 4, 8, 12 and 24 hours, and feces were collected at 4, 8, 12 and 24 hours.
[0192] Analysis for C2E2, C2E1, and DTPA in plasma and urine was performed using HPLC (Prominence UFLC; Shimadzu, Columbia, Maryland) with a 120 μL flow-through radiochemical detector (Radiomatic 650TR; PerkinElmer). In addition, total14C content was analyzed by adding aliquots of plasma and urine directly to 10 mL of scintillation cocktail (Ultima Gold; PerkinElmer, Waltham, Massachusetts) and analyzing by liquid scintillation counting (LSC; Tri-Carb 3110 TR, PerkinElmer). The LSC data were corrected for quenching using an external standard. Feces were diluted with a 1: 1 mixture of acetonitrile and 25 mM citrate buffer (pH 4.0) and homogenized in polycarbonate vials containing steel grinding balls. The homogenization was performed by shaking the vials on a high throughput homogenizer (PowerGen; Thermo Fisher Scientific, Waltham, Massachusetts) for 5-8 min at high speeds. Approximately 200 mg of each homogenate was sampled and combined with 1 mL of SOLVABLE® (PerkinElmer) and heated in an oven at 60°C for 1-3 h until digestion was visibly complete. Once the samples were cooled, hydrogen peroxide (30% in water) was added in two aliquots of 100 pL to decolorize the sample. The samples were returned to the 60°C oven for an additional 1 h. After cooling, each sample was diluted with 10 mL of scintillation cocktail and analyzed by LSC. The radioactivity measured in each sample was weight-corrected to determine the total radioactivity in each whole tissue.
[0193] The inability to synthesize large quantities of14C-C2E2 resulted in low plasma14C concentrations and the HPLC / Radiomatic detector could not be used to determine the species present. The samples were therefore analyzed by liquid scintillation counting. However, the plasma14C concentrations were still too low to determine concentration time profiles over 24 hours. High14C concentrations were observed in the urine and the14C content must arise from C2E2 absorbed prior to elimination. During the study, oral groups were administered a 600-mg dose containing 50 mg of14C-C2E2 and IV groups received 50 mg of pure14C-C2E2. Assuming that 99% of the dose is eliminated within 24 hours, then a comparison between the total quantity of14C observed in the urine of IV and oral groups can be used to approximate the fraction of C2E2 absorbed. For fasted and ad lib rats the fraction of14C material seen in the urine compared to the IV group was 0.42 and 0.48, respectively.An additional assessment of C2E2 oral bioavailability in rats was conducted using non-radioactive C2E2. Jugular-cannulated female Sprague-Dawley rats (226-250 g; n = 3 per time point) were divided into two groups and administered either a single IV (16.9 mg / kg; caudal vein) or PO (84 mg / kg) dose of C2E2 (water) under ad lib conditions. All rats had a pre-dose sample drawn on the day of dosing. Blood was collected from the jugular catheter (0.7 mL per draw; 5 blood draws / animal) at 0.083, 0.25, 0.5, 1. 3, and 8 h post dose and immediately transferred to chilled vacutainer tubes containing 5 mg sodium fluoride and 4 mg potassium oxalate. These tubes were inverted to ensure proper mixing and placed on ice until centrifugation. Tubes were centrifuged at 1,300 x g for 10 minutes at 4°C within 5 minutes of collection. Aliquots of plasma were then divided into chilled 1.7 mL microcentrifuge tubes within 5 minutes of centrifugation.
[0194] The plasma concentrations of C2E2 and its metabolites, C2E1 and DTPA were quantified using two LC / MS / MS methods. One method was used for C2E2 and C2E1 and another for DTPA. For C2E2, 100 pl of the acidified samples was treated with 400 pL acetonitrile containing internal standard (13C5-C2E5) followed by mixing and centrifugation.
[0195] 400 pL of the supernatant was subsequently removed, evaporated and reconstituted with 500 pL water / acetonitrile / formic acid (85 / 15 / 0.1) for injection. The separation of the components was performed on a YMC ODS-AM (100 x 2.1 mm, 3.5 pm) column with a mobile phase gradient starting with 0.1% formic acid in water and ending with 0.1 % formic acid in acetonitrile. The compounds were detected on a triplequadrupole mass spectrometer using heated electrospray ionization in the positive-ion mode. For DTPA, an excess of Fe(III) was utilized to ensure formation of an Fe(III)-DTPA complex for quantification. A13C5-DTPA internal standard was used. 100 pl of the acidified samples was treated with 50 pL of 2 mM Fe(III)C12 and allowed to incubate for 90 minutes. Acetonitrile (400 pL) containing internal standard was added. After mixing and centrifugation, 350 pL of the supernatant was removed, evaporated and reconstituted with 100 pL of mobile phase. Separation was performed using a Phenomenex Luna phenyl-hexyl (150 x 2mm, 3 pm) column with a mobile phase gradient starting with water / methanol (90 / 10) with 1 mM acetic acid and 1 mM tributylamine and ending with acetonitrile / methanol (50 / 50) with 1 mM acetic acid and 1 mM tributylamine. The DTPA was detected on a triple-quadrupole mass spectrometer using heated electrospray ionization in the negative-ion mode. Quantification of C2E2 and DTPA was based on the peakareas of analyte to their respective internal standards. The range of quantification was 100 to 100,000 ng / mL for C2E2, 5 to 1,000 ng / mL for C2E1 and 10 to 1,000 ng / mL for DTPA.
[0196] Pharmacokinetic parameters in plasma were determined from concentration-time profiles by established non-compartmental methods using WinNonlin® Version 5.2.
[0197] Following both oral and IV administration, the parent molecule C2E2 was the most abundant circulating analyte in rats. C2E1 and DTPA were observed in plasma at substantially lower levels than C2E2 (see FIG. 5). The synthetic impurity, C2E3, was also observed in plasma of rats at very low levels after an IV dose of C2E2 (C2E3 was not detected after the oral C2E2 dose).
[0198] Tmax values ranging from 0.25 to 1.00 hours were attained for C2E2 and metabolites following oral administration, while ti / 2 values ranged from 5.85 to 8.44 hours. Oral bioavailability was calculated from the area under the plasma concentration vs. time curve (AUC) values of C2E2 and under these experimental conditions the absolute oral bioavailability of C2E2 in female Sprague-Dawley rats was 29%. Exposure to C2E2 (AUC) generally increased with the increase in C2E2 dose level, but increases in C2E2 Cmax and AUC0-24 were not consistently proportional. Sex differences in C2E2 Cmaxand AUC0-24 values were generally less than 2-fold, and no accumulation of C2E2 was observed after multiple dosing of C2E2 in rats.
[0199] Example 20. (Prophetic). In vitro Radiometal / Radioconjugate Competition / Transchelation Study
[0200] Methods
[0201] In vitro Radiometal Competition Assay with 177Lu
[0202] 1. DOTA-conjugated test material (TA) (e.g., DOTA-PSMA-617) and 177Lu will be obtained.
[0203] 2. TA will be radiolabelled with 177Lu.
[0204] 3. RP-HPLC conditions will be optimized prior to conducting the study.
[0205] 4. 177Lu-DOTA-TA or control free radiometal (177Lu) will be incubated in assay buffer with increasing concentrations of C2E2 for durations of up to four different time points (5 minutes, 1 hour, 24 hours, and 48 hours).5. Parent bound (177Lu-DOTA-TA), free radiometal (177Lu), and newly formed complexes with C2E2 will be analyzed at each time point using RP-HPLC with radiodetection.
[0206] 6. The percentage of parent bound (177Lu-DOTA-TA), free radiometal (177Lu), and newly formed complexes with C2E2 present at each time point with each C2E2 concentration will be determined.
[0207] In vitro Radiometal Competition Assay with 225 Ac
[0208] 1. DOTA-conjugated test material (TA) (e.g., DOTA-PSMA-617) and 225 Ac will be obtained.
[0209] 2. TA will be radiolabelled with 225 Ac.
[0210] 3. RP-HPLC conditions will be optimized prior to conducting the study.
[0211] 4. 225Ac-DOTA-TA or control free radiometal (225Ac) will be incubated in assay buffer with increasing concentrations of C2E2 for durations of up to four different time points (5 minutes, 1 hour, 24 hours, and 48 hours).
[0212] 5. Parent bound (225Ac-DOTA-TA), free radiometal (225 Ac), and newly formed complexes with C2E2 will be analyzed at each time point using RP-HPLC with radiodetection.
[0213] 6. The percentage of parent bound (225Ac-DOTA-TA), free radiometal (225Ac), and newly formed complexes with C2E2 present at each time point with each C2E2 concentration will be determined.
[0214] In vitro Radiometal Competition Assay with 203Pb
[0215] 1. DOTA-conjugated test material (TA) (e.g., DOTA-PSMA-617) and 203Pb will be obtained.
[0216] 2. TA will be radiolabelled with 203Pb.
[0217] 3. RP-HPLC conditions will be optimized prior to conducting the study.
[0218] 4. 203Pb-DOTA-TA or control free radiometal (203Pb) will be incubated in assay buffer with increasing concentrations of C2E2 for durations of up to four different time points (5 minutes, 1 hour, 24 hours, and 48 hours).5. Parent bound (203Pb-DOTA-TA), free radiometal (203Pb), and newly formed complexes with C2E2 will be analyzed at each time point using RP-HPLC with radiodetection.
[0219] 6. The percentage of parent bound (203Pb-DOTA-TA), free radiometal (203Pb), and newly formed complexes with C2E2 present at each time point with each C2E2 concentration will be determined.
[0220] Results:
[0221] 1. Selectivity for Free vs. Chelated Radiometal
[0222] The chelating agent C2E2, when incubated with177Lu-DOTA-PSMA-617,225Ac-DOTA-PSMA-617. or203Pb-DOTA-PSMA-617 at concentrations ranging from low to high across timepoints of 5 minutes to 48 hours, will not substantially reduce the percentage of parentbound radioconjugate relative to vehicle control, thereby demonstrating that C2E2 preferentially chelates free radiometal species rather than competing for radiometals already stably coordinated within a macrocyclic DOTA complex.
[0223] 2. Absence of Trans-Chelation Activity
[0224] Administration of C2E2 to a solution containing pre-formed [177Lu]-, [225Ac]-, or [203Pb]-DOTA radioconjugates will not result in a statistically significant increase in free radiometal or newly formed C2E2-radiometal complexes detectable by reverse-phase HPLC with radiodetection, indicating that C2E2 lacks meaningful trans-chelation activity against radiometals coordinated within the kinetically inert DOTA cage under physiological conditions.
[0225] 3. Chelating Free Radiometal
[0226] The chelating agent C2E2, when incubated with177Lu,225Ac, or203Pb at concentrations ranging from low to high across timepoints of 5 minutes to 48 hours, will chelate over 90% of free radiometal within 1 hour.
[0227] 4. Concentration-Independent Sparing of DOTA-Bound Radiometal
[0228] Across a range of C2E2 concentrations spanning at least three orders of magnitude, the percentage of intact radiometal-DOTA-targeting agent complex will remain substantially unchanged relative to vehicle-treated controls for each of177Lu,225Ac, and203Pb, establishing that the non-competitive behavior of C2E2 with respect to DOTA-coordinated radiometals isconcentration-independent and consistent with a mechanism of action restricted to sequestration of dissociated or free ionic radiometal species.
[0229] Example 21. (Prophetic). Human clinical trial of C2E2 to lessen adverse events with Lu-177-PSMA-617 treatment of castration-resistant metastatic prostate cancer.
[0230] In this trial, patients with castration-resistant metastatic prostate cancer being treated with Lu-177-PSMA-617 are randomized to receive oral placebo or oral C2E2 at a dose of 500 mg twice per day for 14 days after each dose of Lu-177-PSMA-617 beginning on the day of dosing.
[0231] Patients are evaluated for progression-free survival and adverse events tracked.
[0232] It is expected that the C2E2-dosed group will exhibit a statistically significant reduction in the rate of total and Grade >3 treatment-emergent adverse events, particularly fatigue, thrombocytopenia, lymphopenia, leukopenia, anemia, and xerostomia, with no statistically significant difference between the groups in progression-free survival or overall survival, demonstrating that orally administered C2E2 widens the therapeutic window of Lu-177-PSMA-617 by reducing off-target toxicity without compromising tumor-targeted antitumor efficacy.
Claims
CLAIMSWhat is claimed is:
1. A method of reducing side effects from a medical diagnostic or therapeutic procedure that comprises internal systemic administration to a patient of a toxic cationic metal complex:wherein the cationic metal complex comprises a cationic metal with a charge of +2 or more complexed to a chelator and the cationic metal is toxic;the method comprising:orally administering a binding agent of formula I the same day as or 7 or fewer days after the internal administration of the cationic metal complex,Iwherein R= —OR1or —NHR2;R’=same or different and is independently selected from H, C1-C30 alkyl, C2- C30 alkenyl, C2-C30 alkynyl or benzyl and at least one R1is not hydrogen: andR2=same or different and is independently selected from C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl, benzyl or phenylalanine ethyl ester.
2. The method of claim 1 wherein the method is a method of reducing side effects from a medical therapy comprising internal systemic administration of a targeted cationic radionuclide complex:wherein the cationic metal complex is a targeted cationic radionuclide complex and comprises a cationic radionuclide complexed to a chelator;wherein the chelator comprises a targeting moiety that selectively binds to a particular tissue or cell type and the targeted cationic radionuclide complex is targeted to selectively bind to the particular tissue or cell type.
3. The method of claim 1 wherein the medical procedure is a medical resonance imaging (MRI) procedure that comprises internal administration of gadolinium;wherein the toxic cationic metal is gadolinium;wherein the method comprises:orally administering the compound of chemical formula I the same day as or 7 or fewer days after the internal administration of the gadolinium.
4. The method of claim 1 wherein R=OR1and R1=same or different and is independently selected from C1-C6 alkyl and H and at least one R1is C1-C6 alkyl.
5. The method of claim 4 wherein two R1are C1-C6 alkyl and two R1are H.
6. The method of claim 5 wherein the compound of chemical formula I is C2E2.
7. The method of claim 1 wherein the step of orally administering the compound of formula I reduces tissue accumulation of the cationic metal.
8. The method of claim 2 wherein the step of orally administering the compound of formula I reduces accumulation of the radionuclide in bone.
9. The method of claim 2 wherein the step of orally administering the compound of formula I reduces incidence of myelosuppression.
10. The method of claim 1 wherein the step of orally administering the compound of formula I reduces deposition of the toxic metal in bone or liver.
11. The method of claim 2 wherein the step of orally administering the compound of formula I reduces deposition of the toxic metal in bone or liver.
12. The method of claim 1 wherein the step of orally administering the compound of formula I reduces at least one of liver damage, kidney damage, pancreatitis, and neurological symptoms.
13. The method of claim 1 wherein the method comprises administering the compound of formula I at a dose of 250 mg to 1500 mg twice daily for 3 to 14 days.
14. The method of claim 1 wherein the method comprises administering the compound of formula I 0 to 6 hours before the toxic cationic complex is administered.
15. The method of claim 1 wherein the method comprises administering the compound of formula I 0 to 6 hours after the cationic metal complex is administered.
16. The method of claim 1 wherein the method comprises administering the compound of formula I at least once daily starting from 1 day before to up to 3 days after the cationic metal complex is administered and ending at 7 to 42 days after the cationic radionuclide complex is administered.
17. The method of claim 1 wherein the chelator comprises a cyclic ring and comprises at least 4 electronegative atoms or groups that bind the cationic metal.
18. The method of claim 17 wherein the chelator comprises a 1,4,7,10-tetraazacyclododecane ring or a diaza- 18-crown-6 macrocycle ring.
19. The method of claim 2 wherein the chelator is PSMA-617.
20. The method of claim 1 wherein the binding agent has a KD at least 4-fold higher than the chelator at physiological pH in aqueous solution.
21. The method of claim 2 wherein the targeted cationic radionuclide complex is177Lu-PSMA-617.
22. The method of claim 2 wherein the radionuclide is an isotope of lutetium, actinium, lead, gallium, samarium, yttrium, thorium, bismuth, terbium, copper, scandium, radium, or a combination thereof."23. The method of claim 2 wherein the radionuclide is selected from the group consisting of Lu-177, Ac-225, Ac-227, Pb-212, Ga-68, Y-90, Sm-153, and Ra-223, and combinations thereof.
24. The method of claim 2 wherein the radionuclide is selected from the group consisting of Pb-212, Ga-68, Y-90, Sm-153, Ra-223, Tb-161, Bi-213, Cu-67, and Sc-4725. The method of claim 3 wherein the method step of orally administering C2E2 occurs within 0 to 24 hours after completion of the MRI procedure.
26. A method of reducing off-target radionuclide toxicity in a patient receiving targeted radioligand therapy, comprising:(a) administering to the patient a targeted cationic radionuclide complex comprising a cationic radionuclide complexed to a targeting chelator that selectively binds a tumor-associated membrane antigen, wherein the targeting chelator has a first dissociation constant (KD-chelator) for the cationic radionuclide at physiological pH; and(b) orally administering to the patient a binding agent of Formula I, the same day as or 7 or fewer days after step (a)wherein R= —OR1or —NHR2;R1=same or different and is independently selected from H, C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl or benzyl and at least one R1is not hydrogen; andR2=same or different and is independently selected from C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl, benzyl or phenylalanine ethyl ester;wherein the binding agent has a second dissociation constant (KD-binding-agent) for the cationic radionuclide at physiological pH that is greater than Ko-chelator and less than the dissociation constant of human serum albumin for the same cationic radionuclide; and wherein the orally administered binding agent scavenges free cationic radionuclide and free radioactive daughter isotopes released in vivo from the targeted cationic radionuclide complex without stripping the cationic radionuclide from the intact targeting chelator.
27. A method of reducing toxicity from alpha-emitting daughter isotopes in a patient receiving a targeted alpha-emitting radionuclide complex, the method comprising:administering to the patient the targeted alpha-emitting radionuclide complex, wherein the alpha-emitting radionuclide undergoes sequential alpha decay to produce daughter isotopes, and wherein the recoil energy of the alpha emission is sufficient to disrupt the chelation of the daughter isotopes by the targeting chelator and release free daughter isotopes into circulation; andorally administering to the patient a binding agent of formula Iwherein R= —OR1or —NHR2;R'-same or different and is independently selected from 11. C1-C30 alkyl, ( '■- C30 alkenyl, C2-C30 alkynyl or benzyl and at least one Rlis not hydrogen; andRfr-sarne or different and is independently selected from C1-C30 alkyl, C2-C30 alkenyl, C2-C30 alkynyl, benzyl or phenylalanine ethyl ester.(as defined in claim 1);wherein the compound of Formula I is administered before, at the same time as, or up to 7 days after the administration of the targeted alpha-emitting radionuclide complex and wherein the orally administered binding agent scavenges the released free daughter isotopes in systemic circulation before deposition of those daughter isotopes into bone marrow, kidney, salivary gland, liver, or other non-target tissue.
28. The method of claim 2 wherein the binding agent has a log Ko for the cationic radionuclide at physiological pH that is at least 1 log unit higher than the log KD of the targeting chelator and at least 1 log unit lower than the log KD of human scrum albumin for the same cationic radionuclide.
29. The method of claim 2 wherein the targeted cationic radionuclide complex is administered in combination with an immune checkpoint inhibitor selected from the group consisting of an anti-PD-1 antibody, an anti-PD-Ll antibody, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-TIGIT antibody, and combinations thereof, wherein the orally administered compound of Formula I reduces myelosuppression caused by the radionuclide, thereby preserving immune function during checkpoint inhibitor therapy.
30. The method of claim 29 wherein the immune checkpoint inhibitor is pembrolizumab, nivolumab, atezolizumab, durvalumab, or ipilimumab.
31. The method of claim 2 wherein the radionuclide is Pb-212, and the orally administered compound of Formula I chelates free Pb-212 and its decay daughter isotopes Bi-212, Po-212, and Tl-208 generated by metabolic dechelation, kinetic dissociation, or alpha-recoil release from the targeted Pb-212 complex.
32. The method of claim 2 wherein the targeted cationic radionuclide complex is administered in two or more sequential cycles, and the compound of Formula I isadministered orally beginning within 24 hours of each cycle and continuing at least once daily for 7 to 42 days after each cycle, and wherein the compound of Formula I is not administered during the 1 to 3 days immediately preceding each subsequent cycle of the targeted cationic radionuclide complex.
33. The method of claim 2 wherein the orally administered compound of Formula I reduces salivary-gland radiation dose and the incidence and severity of xerostomia in the patient as compared to administration of the targeted cationic radionuclide complex without the compound of Formula I.
34. The method of claim 1 wherein the compound of Formula I has a Caco-2 monolayer permeability (Papp) at least 5-fold higher than the Papp of diethylenetriaminepentaacetic acid (DTPA) measured under the same assay conditions.
35. The method of claim 1 wherein the compound of Formula I has an absolute oral bioavailability of at least 15% in a mammalian subject.
36. The method of claim 1 wherein the compound of Formula I is administered without a permeation enhancer.
37. The method of claim 2 wherein the targeting chelator targets a tumor-associated membrane antigen selected from the group consisting of prostate-specific membrane antigen (PSMA), somatostatin receptor 2 (SSTR2), human epidermal growth factor receptor 2 (IIER2), epidermal growth factor receptor (EGFR), fibroblast activation protein (FAP), CD20, CD33, CD38, gastrin-releasing peptide receptor (GRPR), carbonic anhydrase IX (CAIX), and combinations thereof.
38. The method of claim 37 wherein the targeting moiety is PSMA-617, DOTATATE, DOTATOC, FAPI-46, FAPI-04, or trastuzumab.
39. The method of claim 2 wherein the compound of Formula I is administered orally beginning 1 to 7 days prior to the administration of the targeted cationic radionuclide complex and continuing for 7 to 42 days after each administration of the targeted cationic radionuclide complex.
40. The method of claim 2 wherein the patient has Stage I, Stage II, or Stage III cancer at the time of administration of the targeted cationic radionuclide complex, or has compromised baseline renal function, baseline neutrophil count, baseline platelet count, or baseline hemoglobin that would otherwise contraindicate administration of the targeted cationic radionuclide complex.
41. The method of claim 1 wherein the compound of Formula I is administered as an oral capsule, oral tablet, or oral solution, in fasted condition.
42. A method of reducing systemic retention of an internalized radionuclide in a subject following accidental, occupational, or environmental radiological exposure, the method comprising orally administering to the subject a compound of Formula IIwherein R- --OR1or \ H RRl=sarae or different and is independently selected from H, C1-C30 alkyl, C2- C30 alkenyl, C2-C30 alkynyl or benzyl and at least one R1is not hydrogen; andR2=same or different and is independently selected from Ci -C30 alkyl, C2-C 0 alkenyl, C2-C30 alkynyl, benzyl or phenylalanine ethyl ester.(as defined in claim 1);wherein the compound of Formula I is administered within 0 to 7 days after the exposure, in a dose of 250 mg to 1,500 mg, once or twice daily, for 3 to 42 days, thereby reducing soft-tissue and skeletal deposition of the internalized radionuclide.
